Across TCGA pan-cancer cohorts, FAM3B mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FAM3B data layer compared with 23 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FAM3B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated FAM3B expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.
PDAC and HNSC are the cancer types where FAM3B mass-spec protein most reproducibly stratifies survival.